104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026 HB3001 Introduced , by Rep. Norine K. Hammond SYNOPSIS AS INTRODUCED: 215 ILCS 5/356u Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027. LRB104 08415 BAB 18466 b A BILL FOR 104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026 HB3001 Introduced , by Rep. Norine K. Hammond SYNOPSIS AS INTRODUCED: 215 ILCS 5/356u 215 ILCS 5/356u Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027. LRB104 08415 BAB 18466 b LRB104 08415 BAB 18466 b A BILL FOR
104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026 HB3001 Introduced , by Rep. Norine K. Hammond SYNOPSIS AS INTRODUCED:
215 ILCS 5/356u 215 ILCS 5/356u
215 ILCS 5/356u
Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027.
LRB104 08415 BAB 18466 b LRB104 08415 BAB 18466 b
LRB104 08415 BAB 18466 b
A BILL FOR
HB3001LRB104 08415 BAB 18466 b HB3001 LRB104 08415 BAB 18466 b
HB3001 LRB104 08415 BAB 18466 b
1 AN ACT concerning regulation.
2 Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
4 Section 5. The Illinois Insurance Code is amended by
5 changing Section 356u as follows:
6 (215 ILCS 5/356u)
7 Sec. 356u. Pap tests and prostate cancer screenings.
8 (a) A group policy of accident and health insurance that
9 provides coverage for hospital or medical treatment or
10 services for illness on an expense-incurred basis and is
11 amended, delivered, issued, or renewed after January 1, 2024
12 shall provide coverage, without imposing a deductible,
13 coinsurance, copayment, or any other cost-sharing requirement,
14 for all of the following:
15 (1) An annual cervical smear or Pap smear test for all
16 insureds.
17 (2) An annual prostate cancer screening for insureds
18 upon the recommendation of a physician licensed to
19 practice medicine in all its branches for:
20 (A) asymptomatic individuals age 50 and over;
21 (B) African-American individuals age 40 and over;
22 and
23 (C) individuals age 40 and over with a family
104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026 HB3001 Introduced , by Rep. Norine K. Hammond SYNOPSIS AS INTRODUCED:
215 ILCS 5/356u 215 ILCS 5/356u
215 ILCS 5/356u
Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027.
LRB104 08415 BAB 18466 b LRB104 08415 BAB 18466 b
LRB104 08415 BAB 18466 b
A BILL FOR
215 ILCS 5/356u
LRB104 08415 BAB 18466 b
HB3001 LRB104 08415 BAB 18466 b
HB3001- 2 -LRB104 08415 BAB 18466 b HB3001 - 2 - LRB104 08415 BAB 18466 b
HB3001 - 2 - LRB104 08415 BAB 18466 b
1 history of or genetic predisposition to prostate
2 cancer.
3 (3) Surveillance tests for ovarian cancer for insureds
4 who are at risk for ovarian cancer.
5 (b) This Section shall not apply to agreements, contracts,
6 or policies that provide coverage for a specified disease or
7 other limited benefit coverage.
8 (c) This Section does not apply to coverage of prostate
9 cancer screenings to the extent such coverage would disqualify
10 a high-deductible health plan from eligibility for a health
11 savings account pursuant to Section 223 of the Internal
12 Revenue Code.
13 (d) For the purposes of this Section:
14 "At risk for ovarian cancer" means:
15 (1) having a family history (i) with one or more
16 first-degree relatives with ovarian cancer, (ii) of
17 clusters of relatives with breast cancer, or (iii) of
18 nonpolyposis colorectal cancer; or
19 (2) testing positive for BRCA1 or BRCA2 mutations; or .
20 (3) having a high level of CA-125, as indicated by a
21 blood test screening.
22 "Prostate cancer screening" means medically viable methods
23 for the detection and diagnosis of prostate cancer, including
24 a digital rectal exam and the prostate-specific antigen test
25 and associated laboratory work. "Prostate cancer screening"
26 includes medically necessary subsequent follow-up testing as
HB3001 - 2 - LRB104 08415 BAB 18466 b
HB3001- 3 -LRB104 08415 BAB 18466 b HB3001 - 3 - LRB104 08415 BAB 18466 b
HB3001 - 3 - LRB104 08415 BAB 18466 b
1 directed by a health care provider, including, but not limited
2 to:
3 (1) urinary analysis;
4 (2) serum biomarkers; and
5 (3) medical imaging, including, but not limited to,
6 magnetic resonance imaging.
7 "Surveillance tests for ovarian cancer" means all
8 medically viable methods for the detection and diagnosis of
9 ovarian cancer, including, but not limited to, ultrasounds,
10 magnetic resonance imagings (MRIs), x-rays, computed
11 tomography (CT) scans, and CA-125 blood test screenings.
12 annual screening using (i) CA-125 serum tumor marker testing,
13 (ii) transvaginal ultrasound, (iii) pelvic examination.
14 (Source: P.A. 102-1073, eff. 1-1-23; 103-30, eff. 1-1-25.)
HB3001 - 3 - LRB104 08415 BAB 18466 b